Eversept Partners
$1.8B 13F equity value
135 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Eversept Partners covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| UTHR | UNITED THERAPEUTICS CORP DEL | 287,668 | $156M | 8.5% |
| ABVX | ABIVAX SA | 913,880 | $122M | 6.6% |
| EHC | ENCOMPASS HEALTH CORP | 1,026,919 | $104M | 5.7% |
| ENSG | ENSIGN GROUP INC | 602,079 | $97M | 5.3% |
| VERA | VERA THERAPEUTICS INC | 2,212,770 | $95M | 5.2% |
| CLDX | CELLDEX THERAPEUTICS INC NEW | 1,785,941 | $66M | 3.6% |
| SNDX | SYNDAX PHARMACEUTICALS INC | 2,798,210 | $61M | 3.3% |
| BKD | BROOKDALE SR LIVING INC | 3,396,470 | $55M | 3.0% |
| IONS | IONIS PHARMACEUTICALS INC | 664,684 | $53M | 2.9% |
| NTRA | NATERA INC | 175,807 | $48M | 2.6% |
Track Eversept Partners's 13F portfolio: $1.8B in reported holdings, 135 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}